Tempest Therapeutics Inc

NASDAQ TPST

Data sourced from

and

Download Data

Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 79.76%

Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted 1 year YoY Change (%) is 79.76% for the Trailing 12 Months (TTM) ending March 31, 2024, a 4.61% change year over year. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -2.66, a 76.24% change year over year.
Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -11.18, a -362.98% change year over year.
Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -2.41, a 47.16% change year over year.
Tempest Therapeutics Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -4.57.

NASDAQ: TPST

Tempest Therapeutics Inc

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	17
Sector	Healthcare
Industry	Biotechnology

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key trends